1. Finland Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Orion Oyj

Orion Oyj

ORNAV.HE
Orion OyjFI flagNASDAQ Helsinki
70.90
EUR
-0.70
- -
10.02BMarket Cap
Orion Oyj
ORNAV.HE
(NASDAQ Helsinki)

Recent

price

70.90

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
6.03
6.52
6.96
7.14
7.22
7.21
7.63
7.35
6.95
7.48
7.67
7.41
9.54
8.48
10.98
13.43
11.92
Revenue per Share
1.31
1.49
1.47
1.46
1.5
1.48
1.77
1.61
2.35
1.43
1.57
1.38
2.49
1.54
2.35
3.56
2.69
Basic EPS, GAAP
1.23
1.09
1.22
1.01
1.71
1.5
1.43
1.08
1.17
1.67
1.84
0.93
2.57
0.02
1.47
1.56
1.55
Free Cash Flow per Basic Share
1.1
1.26
1.42
1.3
1.25
1.3
1.31
1.55
1.45
1.5
1.5
1.5
1.5
1.6
1.62
1.64
1.63
Dividend per Share
3.12
3.42
3.61
3.63
3.61
4.17
4.54
4.81
5.47
5.53
5.6
5.49
6.5
6.43
7.19
9.13
6.54
Book Value per Share
2.73
2.95
3.08
3.14
3.21
3.82
4.18
4.46
5.04
5.18
4.9
4.83
5.1
4.92
5.91
7.8
5.22
Tangible Book Value per Share
141
141
141
141
141
141
141
141
141
141
141
141
141
140
140
141
141
Basic Weighted Avg Shares
850
918
980
1,007
1,015
1,016
1,074
1,034
978
1,051
1,078
1,041
1,341
1,190
1,542
1,890
1,677
Sales/Revenue/Turnover
29.91
30.66
28.32
26.27
26.75
26.36
27.22
27.44
25.69
23.94
25.64
22.83
32.54
22.29
26.88
33.29
28.46
Operating Margin (%)
39
42
40
38
40
42
41
42
42
56
56
46
48
52
93
57
- -
Depreciation Expense
185
210
207
206
211
208
249
226
330
200
220
194
350
217
330
500
378
Net Income, GAAP
26.88
25.67
25.2
21.89
21.14
20.66
19.91
21.1
20.53
20.14
20.98
20.02
20.62
20.26
20.14
20.31
20.18
Effective Tax Rate (%)
21.73
22.82
21.11
20.48
20.81
20.5
23.19
21.87
33.79
19.07
20.4
18.62
26.07
18.22
21.39
26.48
22.54
Profit Margin (%)
292
290
337
432
438
441
461
441
414
412
530
481
603
561
742
784
467
Working Capital
88
66
107
233
210
178
150
150
1
7
106
105
197
171
297
115
136
LT Debt
467
500
510
514
515
595
641
680
773
779
731
748
908
890
1,005
1,284
920
Total Equity
31.95
35.3
33.25
28.94
28.11
27.68
29.49
27.33
22.6
23.26
26.58
22.16
34.67
18.9
26.92
33.32
33.47
Return on Invested Capital (%)
35.05
37.71
34.37
29.6
28.51
27.97
32.26
28.35
38.16
23.67
26.23
21.93
34.95
19.82
27.54
34.62
33.34
Return on Capital (%)
44.12
45.5
41.8
40.43
41.42
37.99
40.61
34.36
45.65
25.9
28.13
24.89
41.5
23.88
34.5
43.6
44.71
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
30
30
182
LT Borrowings
291
- -
- -
LT Finance Leases
6
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
141
141
141
Market Capitalization
5,998
7,604
8,903

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
1,016
1,084
1,008
Cash, Cash Equivalents & STI
206
259
184
Accounts Receivable, Net
255
288
252
Inventories
419
433
442
Total Current Liabilities
274
278
541
Payables & Accruals
- -
- -
- -
ST Debt
30
30
182
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.46%
12.49%
27.81%
Free Cash Flow
935.18%
1,864.03%
6.15%
Net Income, GAAP
16.12%
26.86%
51.65%
Sales/Revenue/Turnover
7.29%
13.25%
22.5%
Total Cash Common Dividend
- -
- -
1.36%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
308
328
471
434
1,542
2025
355
416
695
- -
1,890
2026
418
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.31
0.37
1.14
0.52
2.35
2025
0.44
0.59
1.85
- -
3.56
2026
0.64
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.81
- -
0.81
1.62
2025
- -
0.83
0.82
- -
1.64
2026
- -
- -
- -
- -
- -
Similar Companies
Novo Nordisk A/S (NONOF)
Bayer AG (BAYN.SW)
Ono Pharmaceutical Co., Ltd. (OPHLF)
PT Kalbe Farma Tbk (PTKFY)
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd (600671.SS)
AbbVie Inc. (ABBV.BA)
Business
Orion Oyj is a Finnish pharmaceutical company that develops, manufactures, and markets human and veterinary pharmaceuticals along with active pharmaceutical ingredients (APIs). Its product portfolio comprises patented prescription drugs focused on neurological disorders, oncology, respiratory diseases, cardiovascular diseases, hormonal and urological conditions; generic, over-the-counter (OTC), and biosimilar medicines; veterinary medicines and animal well-being products; and pharmaceutical ingredients and contract manufacturing services. Flagship products include Nubeqa for prostate cancer, Easyhaler inhalation products, Stalevo and Comtess/Comtan for Parkinson's disease, Simdax for acute decompensated heart failure, and sedatives such as Precedex and Dexdor. The company also offers veterinary drugs such as Bonqat, Clevor, Domosedan, and Sileo. Orion operates primarily in Finland, Scandinavia, other parts of Europe, North America, and globally, with most manufacturing and R&D facilities located in Finland. Founded in 1917, Orion is headquartered in Espoo, Finland. In recent developments, Orion has achieved significant sales growth driven by the blockbuster performance of Nubeqa, which surpassed EUR 1 billion in sales in 2024. The company saw a 35.3% year-over-year increase in net sales in Q4 2024 and overall strong financial results with rising operating profits. Orion is investing in capacity expansion, particularly for Easyhaler products and the Nubeqa production line at its Fermion site in Hanko, Finland. Strategic alliances include a discovery service and commercial license agreement with Invenra for bispecific antibody cancer therapeutics and collaboration with Abilita Therapeutics for innovative antibody therapeutics. Orion also leverages artificial intelligence technologies for drug innovation. The company recently secured a EUR 180 million milestone payment related to Nubeqa sales and maintains a positive outlook for continued growth in 2025. Orion’s business segments comprise prescription pharmaceuticals, self-care products, veterinary pharmaceuticals, and contract manufacturing services. Its target markets include specialist and general practitioners, hospitals, pharmacies, veterinarians, healthcare centers, and clinics. Orion’s comprehensive focus covers therapeutic areas such as oncology, neurology, respiratory diseases, cardiovascular diseases, and animal health. The company’s longstanding presence and strategic innovation activities position it as a leading pharmaceutical group in the Nordic region and a competitive global player in specialty human and veterinary medicines.